Why Is REVOLUTION MEDICINES (RVMD) Stock Down Today?

Revolution Medicines (RVMD) shares fell 5.37% to $182.69 on November 11, 2026. The primary driver of the decline appears to be a sharp intraday reversal following the company’s presentation at the Guggenheim Healthcare Innovation Conference, where executives discussed recent quarterly results.

What Happened

The stock opened at $196.00, marking a 1.5% gap up from the prior close of $193.06. However, the initial strength did not hold. The session high was recorded at the open at 7:00 AM ET, after which the price trended lower throughout the morning. By 10:45 AM ET, the stock had reached a session low of $181.01. The company presented at the 3rd Annual Guggenheim Healthcare Innovation Conference on November 10, 2026, with Mark Goldsmith among the participants. A slide deck for the 2026 Q3 earnings call was also published around the same time.

Despite the intraday drop, several analysts maintained positive stances on the stock in the days leading up to the move. HC Wainwright & Co. maintained a Buy rating and raised its price target to $350. TD Cowen also maintained a Buy rating, raising its target to $270. RBC Capital maintained an Outperform rating and increased its price target to $321.

What The Data Shows

Trading volume was light, with 0.4 million shares traded so far, which is 0.2 times the three-month daily average. The company has a market capitalization of $43.3 billion and remains unprofitable, with trailing twelve-month earnings per share of negative $9.14. Revenue has declined 97.2% over the trailing twelve months. The stock has a beta of 1.43 and trades within a 52-week range of $61.50 to $224.31. Over the last eight sessions, the stock had moved up 0.9% from $191.31 to $193.06.

Insider activity has been predominantly selling. In the last 90 days, there were 19 sells totaling $78.4 million and no buys. Recent Form 4 filings show sales by Anthony Mancini on October 26, 2026, Alan B. Sandler on September 29, 2026, and Jeff Cislini on September 25, 2026. Congressional disclosures indicate two buys by Donald J. Trump in June and July 2026, each in the $1,001 to $15,000 range. Social media chatter has been minimal, with only one post in the last seven days.

What To Watch

Investors will monitor the stock’s reaction to the recent analyst price target increases and the continued trend of insider selling. The next scheduled earnings date is not provided in the current data, but coverage breadth remains active with recent conference transcripts and earnings presentations.